Administration of antivascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in the XXXX .

@entity2608 @entity1420 @entity25452 @entity53
Angiogenic factors, including @entity25452 ( @entity25452 ), are expressed during follicular development. Our objective was to investigate the role of @entity25452 in the early follicular phase to test whether early cyclic follicle development and selection are angiogenesis-dependent processes. After documentation of two normal ovulatory cycles, female @entity2608 (n = 6) received five iv injections of anti- @entity25452 receptor 2 (anti- @entity25452 -R2) antibody at 3-d intervals starting on cycle d 2-4. To evaluate nonspecific effects of the treatment antibody, all monkeys also received iv injections of nonspecific humanized mouse IgG, using an identical regimen. Daily measurements of FSH, LH, @entity53 , and @entity1420 were obtained, throughout the entire period, to monitor cyclicity. Administration of anti- @entity25452 -R2 antibody resulted in a significant decline in mean inhibin B levels [control, 181.0 +/- 29.6 (mean +/- SE); treatment d 2, 44.5 +/- 13.1 pg/ml; P < 0.05]. No decrease was observed after IgG treatment. Anti- @entity25452 -R2 antibody treatment also delayed the first significant increase in @entity53 and lengthened the follicular phase from 10-12 d in the preceding two control cycles to 20-42 d in treatment cycles. FSH and LH concentrations increased significantly, within 24 h after anti- @entity25452 -R2 antibody treatment, to levels 2-2.5 times over controls. Our results demonstrate that anti- @entity25452 -R2 antibody therapy in the early follicular phase interferes with the normal development of the cohort of recruited antral follicles. The data clearly indicate that the recruitment-selection process of follicles in the early follicular phase in the nonhuman primate is controlled by @entity25452 , through the @entity25452 -R2.
